Categories

ASCO in Action: FDA Removes Risk Evaluation Management Strategies (REMS) for ESAs

On April 13, the U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategy (REMS) requirements for the use of Epogen/Procrit and Aranesp to treat patients with anemia due to associated myelosuppressive chemotherapy.

Read More No Comments

ASCO Policy Statement on Opioid Therapy: Protecting Access to Treatment for Cancer-Related Pain

This policy statement lays out principles that we believe would balance the public health need to mitigate the abuse and misuse of prescription opioids with continued access to appropriate pain management for cancer patients and survivors.

Read More No Comments

ASCO Policy Brief: FDA’s Regulation of Electronic Nicotine Delivery Systems and Tobacco Products

US Food and Drug Administration, US Department of Health and Human Services: Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act: Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products. Final Rule. […]

Read More No Comments

Are you ready for MACRA? Tools and resources to help you prepare – September 23

ASCO Headquarters in Alexandria, Va. 8am–3pm, Friday, September 23, 2016 (breakfast and lunch provided) Click Here for more information

Read More No Comments

The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology

Cancer care in the United States remained a mixed picture in 2015. Declining mortality rates, growing numbers of survivors, and exciting progress in treatment were set against the backdrop of increasingly unsustainable costs and a volatile practice environment. In this third annual State of Cancer Care in America report, the American Society of Clinical Oncology […]

Read More No Comments

U.S. Cancer Care System Ill-equipped to Deliver New Advances to Patients, ASCO Report Finds

The State of Cancer Care in America published March 15 in the Journal of Oncology Practice and presented at a Congressional briefing in Washington, D.C., is ASCO’s third annual assessment of national trends in cancer care delivery. The report highlights many promising cancer care developments, including new drugs and technologies, declining mortality rates, expanded access to healthcare […]

Read More No Comments

Inside Cancer.net: December 2015 Issue

Read the latest from ASCO’s patient website.

Read More No Comments

ASCO News From Genentech

Genentech medicines that represent progress in targeted medicines and immunotherapies: Alectinib, pivotal data showing the investigational ALK inhibitor shrank tumors in about half of the people with advanced ALK-positive non-small-cell lung cancer (NSCLC) following treatment with crizotinib [press release]. Atezolizumab (MPDL3280A; anti-PDL1), data showing the investigational cancer immunotherapy reduced the risk of death by half in […]

Read More No Comments